(2S)-1-cyclopropylpropan-2-ol | 1432621-12-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S)-1-cyclopropylpropan-2-ol
• CAS: 1432621-12-9
• 化学式: C₆H₁₂O
• 分子量: 100.16
• InChiKey: KNQQUHYWTTUEQJ-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Benzolactam compounds as protein kinase inhibitors
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US11001575B1

  公开（公告）日：2021-05-11

  The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.

  本发明提供了一种式 (0) 的化合物： 或其药学上可接受的盐、N-氧化物或同系物；其中 n 是 1 或 2 X 是 CH 或 N Y 选自 CH 和 C-F Z 选自 C-Rz 和 N； R1 选自 -(Alk1)t-Cyc1；其中 t 为 0 或 1； 任选取代的 C1-6 无环烃基团 R2 选自氢、卤素和任选被一个或多个氟原子取代的 C1-3 烃基； R3 是氢或基团 L-R7； R4 选自氢、甲氧基和任选被取代的 C1-3 烷基；以及 R4a 选自氢和 C1-3 烷基； 其中 Rz、Alk1、Cyc1、L1 和 R7 在本文中定义；只要该化合物不是 6-苄基-3-2-[(2-甲基嘧啶-4-基)氨基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮和 3-2-[(2-甲基嘧啶-4-基)氨基]吡啶-4-基}-7,8-二氢-1,6-萘啶-5(6H)-酮及其盐和它们的同系物。 这些化合物是 ERK1/2 激酶的抑制剂，可用于治疗 ERK1/2 介导的疾病。因此，这些化合物可用于治疗，特别是治疗癌症。
• [EN] CRF1 RECEPTOR LIGANDS COMPRISING HETEROARYL FUSED BICYCLES<br/>[FR] LIGANDS DES RÉCEPTEURS DU CRF1 COMPRENANT DES BICYCLES HÉTÉROARYLE CONDENSÉS
  申请人：NEUROGEN CORP

  公开号：WO2007133756A2

  公开（公告）日：2007-11-22

  [EN] Substituted heteroaryl fused pyridine and pyrazine compounds that act as selective modulators of CRFl receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, gastrointestinal disorders, and eating disorders. Methods of treatment of such disorders as well as packaged pharmaceutical compositions are also provided. Compounds provided herein are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
  [FR] L'invention concerne des composés hétéroaryle de pyridine et de pyrazine condensés substitués qui agissent comme des modulateurs sélectifs des récepteurs du CRF1. Ces composés sont utiles dans le traitement de troubles du système nerveux central et de troubles périphériques, en particulier le stress, l'anxiété, la dépression, les troubles cardiovasculaires, les troubles gastro-intestinaux et les troubles de l'alimentation. Des méthodes de traitement de tels troubles ainsi que des compositions pharmaceutiques conditionnées sont également prévues. Les composés décrits sont également utiles comme sondes permettant de localiser les récepteurs du CRF et comme normes dans des dosages de liaison aux récepteurs du CRF. L'invention concerne aussi des procédés d'utilisation desdits composés dans des études de localisation de récepteurs.
• [EN] METHOD OF FORMING SEMICRYSTALLINE POLYETHERIMIDE, AND POLYETHERIMIDE-CONTAINING COMPOSITION<br/>[FR] PROCÉDÉ DE FORMATION DE POLYÉTHERIMIDE SEMI-CRISTALLIN ET COMPOSITION CONTENANT UN POLYÉTHERIMIDE
  申请人：SABIC GLOBAL TECHNOLOGIES BV

  公开号：WO2020234683A1

  公开（公告）日：2020-11-26

  In a method of forming a semicrystalline polyetherimide, a solvent mixture is combined with an amorphous polyetherimide in a weight ratio of 1 : 1 to 50: 1, respectively, to form a first dispersion. The solvent mixture includes dichloromethane and a C1-C6 alkanol in a weight ratio of 0.5:1 to 15: 1, respectively. The first dispersion is agitated to form a second dispersion containing a semicrystalline polyetherimide, and the semicrystalline polyetherimide is isolated from the second dispersion. The isolated semicrystalline polyetherimide exhibits a melting point in a range of 230 to 300 °C. Also described is a composition that includes a polyetherimide, dichloromethane, and a C1-C6 alkanol in specific ratios.